MIA in the spotlight at ASCO virtual conference
30 May 2020
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting has gone virtual, with researchers from MIA once again in the spotlight. Usually attended by over 40,000 professionals, ASCO’s Annual Meeting showcased global advances in research and treatment, all of which impact patient outcomes.
Headlining MIA’s contribution at ASCO 20 Virtual was Dr Ines Silva, a clinical fellow and post-doctoral researcher at MIA, who was awarded the prestigious Bradley Stuart Beller Endowed award for best abstract.
Dr Silva’s abstract related to an oral presentation delivered virtually at ASCO, assessing the impact of Ipilimumab-based immunotherapy in patients with metastatic melanoma whose disease had already proven resistant to anti-PD1 monotherapy.
The multicentre retrospective study involved 355 patients with Stage III or Stage IV melanoma whose cancer had progressed or recurred despite having anti-PD1 monotherapy. 46% of these patients were then treated with ipilimumab alone, with 54% receiving combination ipilimumab and anti-PD1 therapy.
In patients who received the follow up combination therapy, there was a higher response rate (32%) as well as longer progression free survival (25% at 12 months) and overall survival (58% at 12 months) compared to IPI alone. Importantly, IPI+anti-PD1 was not associated with more severe side effects than IPI monotherapy.
Dr Silva and the MIA team created clinical predictive models to help identify the patients who will benefit from these treatments.
‘It was an honour to deliver the oral presentation virtually at ASCO 20 Virtual,’ said Dr Silva. ‘Although we weren’t together physically, still being able to share insights and learnings globally was vitally important in ensuring we continue on our path to saving more lives from melanoma.’
Also awarded at ASCO 20 Virtual were Dr Adriana Hepner and Dr Lauren Brown who received merit awards for abstracts submitted. Overall, MIA researchers and clinicians contributed to 21 abstracts featured at ASCO.
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way in changing the treatment landscape for melanoma patients,’ MIA Co-Medical Director Professor Georgina Long said.
‘Our mission is zero deaths from melanoma, and by collaborating with our colleagues on the world stage we are confident we are on track to reach that goal within our lifetime,’ added MIA Co-Medical Director Professor Richard Scolyer.
Register to view Dr Silva's video and slides here: Dr Silva presentation
See the ASCO 20 Virtual Program here: ASCO 20 Virtual
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.